ArticleScientific reports2026
PERK/ATF4/LAMP3-arm contributes to the aggressive phenotype of hepatocellular carcinoma cells in response to the chronic ethanol exposure.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), the predominant form of liver cancer, is the fifth most prevalent cancer worldwide and second leading cause of cancer-related deaths, underscoring its grim prognosis. Key risk factors for HCC include HBV, HCV, cirrhosis, inherited metabolic diseases, vitamin supplementation, heavy alcohol use, obesity etc. Despite the well-documented impact of alcohol on HCC, there remains a significant gap in understanding alcohol-associated HCC (A-HCC) compared to viral hepatitis associated HCC. So, in this study we tried to elucidate the role of UPR pathway in exacerbating HCC prognosis under the condition of A-HCC. Notably, our RT-qPCR and western blot analysis showed significant upregulation of PERK-ATF4-LAMP3 arm along with CHOP, VEGF-A and nuclear translocation of NF-KB in both HepG2 and Hep3B cell lines. Increased extracellular & intracellular cholesterol and triglyceride levels obtained can be related with the higher expression of SREBP-2 and SREBP-1c respectively. Ethanol exposure also enhanced the invasive and migratory properties of HCC, reduced apoptosis with increased stemness in a PERK dependent manner. Moreover, orally available PERK inhibitor (GSK2606414) successfully relieved the effects caused by ethanol in HepG2 and Hep3B cell lines. In summary, HCC cells gain aggressiveness due to ethanol exposure via PERK/ATF4/LAMP3 pathway, and targeting PERK could serve as a promising therapeutic strategy for A-HCC, mitigating several cancer hallmarks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.